中华实验和临床病毒学杂志
中華實驗和臨床病毒學雜誌
중화실험화림상병독학잡지
CHINESE JOURNAL OF EXPERIMENTAL AND CLINICAL VIROLOGY
2012年
3期
214-217
,共4页
张艳丽%李明慧%刘凤%郝红晓%张洁%刘颖%宋淑静%华文浩%刘敏%谢尧%梁晓峰
張豔麗%李明慧%劉鳳%郝紅曉%張潔%劉穎%宋淑靜%華文浩%劉敏%謝堯%樑曉峰
장염려%리명혜%류봉%학홍효%장길%류영%송숙정%화문호%류민%사요%량효봉
肝炎病毒,乙型%疾病传播,垂直%肝炎疫苗,乙型%免疫接种,加强
肝炎病毒,乙型%疾病傳播,垂直%肝炎疫苗,乙型%免疫接種,加彊
간염병독,을형%질병전파,수직%간염역묘,을형%면역접충,가강
Hepatitis B virus%Disease transmission,vertical%Hepatitis B vaccines%Immunization,secondary
目的 观察乙型肝炎病毒母婴阻断长期效果,探讨HBsAg阳性孕妇生产儿童发生慢性HBV感染的相关影响因素.方法 随访和收集于2004-2006年在北京地坛医院出生的HBsAg阳性母亲所生,并在出生时进行200单位乙肝免疫球蛋白(HBIG)注射和经过乙肝疫苗10μg,0、1和6个月的完整免疫接种程序的儿童静脉血,采用Abbott微粒子化学发光法检测其HBsAg、抗-HBs抗体、抗-HBc抗体,分析母婴阻断和乙肝疫苗接种的长期效果及其影响因素.结果 收集和调查306名儿童年龄3 ～6(4.84)岁,其母亲生产时HBeAg阳性198人,HBeAg阴性92人.10(3.27％)名儿童发生慢性HBV感染.除慢性HBV感染者外,其余296名儿童,20.27％抗-HBs＜10 mIU/ml；44.26％抗-HBs≥10～100 mIU/ml;27.03％抗-HBs≥100 ～ 1000 mIU/ml和8.45％抗-HBs≥1000 mIU/m,抗-HBs保护率为79.73％ (236/296).抗-HBc阳性率为7.43％( 22/296).10例感染儿童的母亲生产时HBeAg均为阳性,HBV DNA均在106拷贝/ml以上,其中8例超过108拷贝/ml.结论 在进行乙肝疫苗加HBIG注射的HBV母婴传播阻断措施下,HBV母婴阻断失败和慢性HBV感染发生在HBeAg阳性和高病毒载量产妇所生婴儿,在有效阻断后仍需进行抗HBs监测并加强免疫接种.
目的 觀察乙型肝炎病毒母嬰阻斷長期效果,探討HBsAg暘性孕婦生產兒童髮生慢性HBV感染的相關影響因素.方法 隨訪和收集于2004-2006年在北京地罈醫院齣生的HBsAg暘性母親所生,併在齣生時進行200單位乙肝免疫毬蛋白(HBIG)註射和經過乙肝疫苗10μg,0、1和6箇月的完整免疫接種程序的兒童靜脈血,採用Abbott微粒子化學髮光法檢測其HBsAg、抗-HBs抗體、抗-HBc抗體,分析母嬰阻斷和乙肝疫苗接種的長期效果及其影響因素.結果 收集和調查306名兒童年齡3 ～6(4.84)歲,其母親生產時HBeAg暘性198人,HBeAg陰性92人.10(3.27％)名兒童髮生慢性HBV感染.除慢性HBV感染者外,其餘296名兒童,20.27％抗-HBs＜10 mIU/ml；44.26％抗-HBs≥10～100 mIU/ml;27.03％抗-HBs≥100 ～ 1000 mIU/ml和8.45％抗-HBs≥1000 mIU/m,抗-HBs保護率為79.73％ (236/296).抗-HBc暘性率為7.43％( 22/296).10例感染兒童的母親生產時HBeAg均為暘性,HBV DNA均在106拷貝/ml以上,其中8例超過108拷貝/ml.結論 在進行乙肝疫苗加HBIG註射的HBV母嬰傳播阻斷措施下,HBV母嬰阻斷失敗和慢性HBV感染髮生在HBeAg暘性和高病毒載量產婦所生嬰兒,在有效阻斷後仍需進行抗HBs鑑測併加彊免疫接種.
목적 관찰을형간염병독모영조단장기효과,탐토HBsAg양성잉부생산인동발생만성HBV감염적상관영향인소.방법 수방화수집우2004-2006년재북경지단의원출생적HBsAg양성모친소생,병재출생시진행200단위을간면역구단백(HBIG)주사화경과을간역묘10μg,0、1화6개월적완정면역접충정서적인동정맥혈,채용Abbott미입자화학발광법검측기HBsAg、항-HBs항체、항-HBc항체,분석모영조단화을간역묘접충적장기효과급기영향인소.결과 수집화조사306명인동년령3 ～6(4.84)세,기모친생산시HBeAg양성198인,HBeAg음성92인.10(3.27％)명인동발생만성HBV감염.제만성HBV감염자외,기여296명인동,20.27％항-HBs＜10 mIU/ml；44.26％항-HBs≥10～100 mIU/ml;27.03％항-HBs≥100 ～ 1000 mIU/ml화8.45％항-HBs≥1000 mIU/m,항-HBs보호솔위79.73％ (236/296).항-HBc양성솔위7.43％( 22/296).10례감염인동적모친생산시HBeAg균위양성,HBV DNA균재106고패/ml이상,기중8례초과108고패/ml.결론 재진행을간역묘가HBIG주사적HBV모영전파조단조시하,HBV모영조단실패화만성HBV감염발생재HBeAg양성화고병독재양산부소생영인,재유효조단후잉수진행항HBs감측병가강면역접충.
Objective To observe the long-term effects of blocking transmission of HBV from mother to children,and explore factors related to development of HBV infection in children of HBsAgpositive mothers.Methods Venous blood specimens were collected from children of HBsAg-positive mothers in Beijing Ditan Hospital from 2004 to 2006.The children had received hepatitis B immunoglobin (HBIG) 200 units at birth and complete immunization program of hepatitis B vaccine 10 μg at birth,1month and 6 months after birth,respectively.Serum HBsAg,anti-HBs antibody and anti-HBc antibody in these samples were detected by using Abbott particles chemiluminescence,and the long-term effects and influencing factors of blocking maternal-infantile transmission and hepatitis B vaccine were analyzed according to the outcomes.Results In this study,306 children were enrolled.Their age was between 3 and 6 year and mean age was 4.84 year.When these children were born,of their 290 mothers,198 were HBeAg-positive and 92 were HBeAg-negative.Ten children (3.27％) developed chronic HBV infection.In the others children,60 (20.27％ ) had anti-HBs less than 10 mIU/ml,131(44.26％ ) between 10 and 100 mIU/ml,80 (27.03％) between 100 and 1000 mIU/ml,and 25 higher than 1000 mIU/ml.Anti-HBs protection rate was 79.73％ (236/296).Anti-HBc positive rate was 7.43％ (22/296).Ten mothers of chronically infected children were HBeAg positive and had high loads of HBV DNA ( ＞106copies/ml) at delivery,of whom eight months had a viral load higher than 108 copies/ml.Conclusion By measures of combined immunization (hepatitis B vaccine and HBIG)to block maternal-infantile transmission of HBV,transmission of HBV and chronic HBV infection occurred to infants born to HBeAg-positive puerpera and high viral load.Children with effective immunization still need to be monitored for anti-HBs and revaccinated if necessary.
